Company Listing
Paratek Pharmaceuticals

Paratek is developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals and Abingworth Partner, Michael Bigham, joined the combined company as Chairman and CEO. Paratek is a VIPE (Venture Investment in Private Equity). The company's lead product is a new broad-spectrum antibiotic in Phase III being developed in both oral and intravenous formulations for serious community-acquired bacterial infections.

BACK
Location
Boston, Massachusetts
CEO
Michael Bigham
Abingworth Partner
Michael Bigham
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Paratek is developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals and Abingworth Partner, Michael Bigham, joined the combined company as Chairman and CEO. Paratek is a VIPE (Venture Investment in Private Equity). The company's lead product is a new broad-spectrum antibiotic in Phase III being developed in both oral and intravenous formulations for serious community-acquired bacterial infections.

Location
Boston, Massachusetts
CEO
Michael Bigham
Abingworth Partner
Michael Bigham
Website Address
BACK
 
Copyright Abingworth 2017